Moquizone is quinazolinone derivative with choleretic and antifibrillatory activity. Oral toxic doses of Moquizone exerted depressant effects, whereas parenteral toxic doses exerted stimulant effects on the central nervous system.

Tuvatidine (HUK 978) is a potent H2-antagonist. HUK 978 was shown to be devoid of activity at the histamine H1-receptor, the muscarinic receptor and the alpha and beta-adrenergic receptors. In both the guinea-pig gastric mucosa preparation and the rat perfused stomach model, HUK 978 was a powerful inhibitor of acid secretion. HUK 978 is a highly specific H2-antagonist and inhibits acid secretion for longer periods than other competitive compounds.

FLUDOXOPONE is an anticholesterolemic agent.

Salafibrate was developed as a hypocholesterolemic agent. Information about the further study of this compound is not available.

Serfibrate, a clofibrate derivative, is a peroxisome proliferator activated receptor-α (PPAR-α) agonist. It is a hypolipidemic agent.

Glybuthiazole is a sulfonamide derivative with antihyperglycemic activity, which possesses anti-diabetic properties. It is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells.

Glicetanile is a derivative of sulphonamides (antibacterial sulfa drugs). It has antihyperglycemic activity. The compound is metabolized and eliminated by the body rapidly after both oral and intravenous administration, and therefore prevents adverse hypoglycemic effects.

Nicoclonate is a nicotinic acid derivative. It is an antilipidemic drug.

Nicanartine [MRZ 3124] is an antioxidant and cholesterol-lowering agent that was under development with Merz + Co. (later Merz Pharma) in Germany. Development of nicanartine for the treatment of atherosclerosis and reperfusion injury was discontinued at the phase I stage.

Siltenzepine is a tricyclic compound. It is an anti-acid agent. It is used in the treatment of peptic ulcers.